Prevalence of SARS-CoV-2 IgG antibodies in an area of northeastern Italy with a high incidence of COVID-19 cases: a population-based study

被引:35
作者
Stefanelli, Paola [1 ]
Bella, Antonino [1 ]
Fedele, Giorgio [1 ]
Pancheri, Serena [2 ]
Leone, Pasqualina [1 ]
Vacca, Paola [1 ]
Neri, Arianna [1 ]
Carannante, Anna [1 ]
Fazio, Cecilia [1 ]
Benedetti, Eleonora [1 ]
Fiore, Stefano [1 ]
Fabiani, Concetta [1 ]
Simmaco, Maurizio [3 ]
Santino, Iolanda [3 ]
Zuccali, Maria Grazia [2 ]
Bizzarri, Giancarlo [2 ]
Magnoni, Rosa [2 ]
Benetollo, Pier Paolo [2 ]
Merler, Stefano [4 ]
Brusaferro, Silvio [5 ]
Rezza, Giovanni [6 ]
Ferro, Antonio [2 ]
机构
[1] Ist Super Sanita, Dept Infect Dis, Rome, Italy
[2] APSS Azienda Prov & Serv Sanit, Trento, Italy
[3] St Andrea Univ Hosp, Hosp Direct & Clin Dept, Rome, Italy
[4] Bruno Kessler Fdn, Ctr Informat Technol, Trento, Italy
[5] Ist Super Sanita, Rome, Italy
[6] Minist Hlth, Hlth Prevent Directorate, Rome, Italy
关键词
IgG; Infection fatality rate; Population-based study; SARS-CoV-2; Seroprevalence; SEROPREVALENCE;
D O I
10.1016/j.cmi.2020.11.013
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: A seroprevalence study of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was conducted in a high-incidence area located in northeastern Italy. Methods: All citizens above 10 years of age resident in five municipalities of the Autonomous Province of Trento, with the highest incidence of coronavirus disease 2019 (COVID-19) cases, were invited to participate in the study. Among 6098 participants, 6075 sera and a standardized questionnaire administered face-to-face were collected between 5 May and 15 May 2020 and examined. Symptomatic individuals and their family contacts were tested by RT-PCR. Anti-SARS-CoV-2 antibodies were detected using an Abbott SARS-CoV-2 IgG assay, which was performed on the Abbott Architect i2000SR automated analyser. Seroprevalence was calculated as the proportion of positive results among the total number tested. A multivariable logistic regression model was performed to assess the relationship between seropositive versus seronegative individuals for a set of explanatory variables. Results: A total of 1402 participants were positive for IgG antibodies against SARS-CoV-2, with a prevalence of 23.1% (1402/6075). The highest prevalence was found in the age class 40-49 years. Overall, 34.4% (2096/6098) of the participants reported at least one symptom. The ratio between reported cases identified by molecular test and those with seropositive results was 1:3, with a maximum ratio of about 1:7 in the age group <20 years and a minimum around 1:1 in those >70 years old. The infection fatality rate was 2.5% (35/1402). Among the symptoms, anosmia and ageusia were strongly associated with seropositivity. Conclusions: The estimated seroprevalence of 23% was three-fold higher than the number of cases reported in the COVID-19 Integrated Surveillance data in the study area. This may be explained in part by a relatively high number of individuals presenting mild or no illness, especially those of younger age, and people who did not seek medical care or testing, but who may contribute to virus transmission in the community. (C) 2020 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.
引用
收藏
页码:633.e1 / 633.e7
页数:7
相关论文
共 50 条
  • [41] Detailed Multiplex Analysis of SARS-CoV-2 Specific Antibodies in COVID-19 Disease
    Brynjolfsson, Siggeir F.
    Sigurgrimsdottir, Hildur
    Einarsdottir, Elin D.
    Bjornsdottir, Gudrun A.
    Armannsdottir, Brynja
    Baldvinsdottir, Gudrun E.
    Bjarnason, Agnar
    Gudlaugsson, Olafur
    Gudmundsson, Sveinn
    Sigurdardottir, Sigurveig T.
    Love, Arthur
    Kristinsson, Karl G.
    Ludviksson, Bjorn R.
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [42] Antibody (IgA, IgG, and IgG Subtype) Responses to SARS-CoV-2 in Severe and Nonsevere COVID-19 Patients
    Patil, Harshad P.
    Rane, Prajakta S.
    Shrivastava, Shubham
    Palkar, Sonali
    Lalwani, Sanjay
    Mishra, Akhilesh C.
    Arankalle, Vidya A.
    VIRAL IMMUNOLOGY, 2021, 34 (03) : 201 - 209
  • [43] Understanding the prevalence of SARS-CoV-2 (COVID-19) exposure in companion, captive, wild, and farmed animals
    Murphy, Hannah L.
    Ly, Hinh
    VIRULENCE, 2021, 12 (01) : 2777 - 2786
  • [44] The COVID-19 wave was already here: High seroprevalence of SARS-CoV-2 antibodies among staff and students in a Cameroon University
    Wondeu, Andrillene Laure Deutou
    Talom, Beatrice Metchum
    Linardos, Giulia
    Ngoumo, Barnes Tanetsop
    Bello, Aichatou
    Soufo, Aurele Marc Ndassi
    Momo, Aime Cesaire
    Doll, Christian
    Tamuedjoun, Alaric Talom
    Kiuate, Jules-Roger
    Cappelli, Giulia
    Russo, Cristina
    Perno, Carlo Federico
    Tchidjou, Hyppolite K.
    Scaramella, Lucia
    Galgani, Andrea
    JOURNAL OF PUBLIC HEALTH IN AFRICA, 2023, 14 (01)
  • [45] SARS-COV-2 IgG specific antibodies persistence in recovered COVID-19 individuals and its association with severity and time of illness
    Pagheh, Abdol Sattar
    Ziaee, Arash
    Romenjan, Khadijeh Abrari
    Rezaei, Fatemeh
    Bahman, Babak
    Alamzadeh, Effat
    Elhamirad, Samira
    Ziaee, Masood
    NEW MICROBES AND NEW INFECTIONS, 2023, 52
  • [46] Population-based study of the durability of humoral immunity after SARS-CoV-2 infection
    Peterhoff, David
    Wiegrebe, Simon
    Einhauser, Sebastian
    Patt, Arisha J.
    Beileke, Stephanie
    Guenther, Felix
    Steininger, Philipp
    Niller, Hans H.
    Burkhardt, Ralph
    Kuechenhoff, Helmut
    Gefeller, Olaf
    Ueberla, Klaus
    Heid, Iris M.
    Wagner, Ralf
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [47] Prevalence and Levels of Anti-SARS-CoV-2 Antibodies in the Eswatini Population and Subsequent Severity of the Fourth COVID-19 Epidemic Wave
    Mutevedzi, Portia C.
    Lokotfwako, Vusie
    Kwatra, Gaurav
    Maphalala, Gugu
    Baillie, Vicky
    Dlamini, Lindiwe
    Dlamini, Senzokuhle
    Mhlanga, Fortune
    Dlamini, Tenelisiwe
    Nhlabatsi, Nhlanhla
    Nunes, Marta C.
    Zwane, Simon
    Madhi, Shabir A.
    COVID, 2024, 4 (03): : 317 - 333
  • [48] Early and High SARS-CoV-2 Neutralizing Antibodies Are Associated with Severity in COVID-19 Patients from India
    Shrivastava, Shubham
    Palkar, Sonali
    Shah, Jignesh
    Rane, Prajakta
    Lalwani, Sanjay
    Mishra, Akhilesh Chandra
    Arankalle, Vidya A.
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2021, 105 (02) : 401 - 406
  • [49] Prevalence and Course of IgA and IgG Antibodies against SARS-CoV-2 in Healthcare Workers during the First Wave of the COVID-19 Outbreak in Germany: Interim Results from an Ongoing Observational Cohort Study
    Reinwald, Mark
    Deckert, Peter Markus
    Ritter, Oliver
    Andresen, Henrike
    Schreyer, Andreas G.
    Weylandt, Karsten Henrich
    Dammermann, Werner
    Lueth, Stefan
    HEALTHCARE, 2021, 9 (05)
  • [50] HERD IMMUNITY TO SARS-CoV-2 AMONG THE POPULATION OF THE REPUBLIC OF BELARUS AMID THE COVID-19 PANDEMIC
    Popova, A. Yu
    Tarasenko, A. A.
    Smolensky, V. Yu
    Egorova, S. A.
    Smirnov, V. S.
    Dashkevich, A. M.
    Svetogor, T. N.
    Glinskaya, I. N.
    Skuranovich, A. L.
    Milichkina, A. M.
    Dronina, A. M.
    Samoilovich, E. O.
    Khamitova, I., V
    Semeiko, G., V
    Amvrosyeva, T., V
    Shmeleva, N. P.
    Rubanik, L., V
    Esmanchik, O. P.
    Karaban, I. A.
    Drobyshevskaya, V. G.
    Sadovnikova, G., V
    Shilovich, M., V
    Podushkina, E. A.
    Kireichuk, V. V.
    Petrova, O. A.
    Bondarenko, S., V
    Salazhkova, I. F.
    Tkach, L. M.
    Shepelevich, L. P.
    Autukhova, N. L.
    Ivanov, V. M.
    Babilo, A. S.
    Navyshnaya, M., V
    Belyaev, N. N.
    Zueva, E., V
    Volosar, L. A.
    Verbov, V. N.
    Likhachev, I., V
    Zagorskaya, T. O.
    Morozova, N. F.
    Korobova, Z. R.
    Gubanova, A., V
    Totolian, Areg A.
    INFEKTSIYA I IMMUNITET, 2021, 11 (05): : 887 - 904